Rodrigo Mallo Leiva on Muck Rack

Rodrigo Mallo Leiva

As seen in: Business Insider, The Astronomical Journal
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rodrigo Mallo

Contact Rodrigo Mallo, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Stellar Occultation by the Resonant Trans-Neptunian Object (523764) 2014 WC510 Reveals a Close Binary TNO

|
By Rodrigo Mallo Leiva, Marc Buie, John Keller, Lawrence H. Wasserman
| The Astronomical Journal Verified
We report on the stellar occultation by (523764) 2014 WC510 observed on 2018 December 1 UT. This occultation campaign was part of the Research and Education Collaborative Occultation Network (RECON), a network of small telescopes spread over 2000 km in western USA and Canada. Light curves from six stations revealed three groups of two or more consecutive flux drops correlated in time between adjacent stations.
Open in Who Shared Issue with article?

Now's the time to invest in biotech, according to VCs who've analyzed 1,227 early-stage biotech startups. Here's why they're so sure.

|
By Rodrigo Mallo Leiva, Eleonora Mantovani
| insider.com
Rodrigo Mallo Leiva and Eleonora Mantovani are Partner and Associate of SOSV's Life Sciences investment team. They've analyzed 1,227 early-stage biotech startups, and believe that investing in biotech companies can result in huge rewards. They reason that this new wave of biotech is worth paying attention to because AI and automation have made it cheaper and easier for companies to build products that solve radically different problems than traditional biotech companies.
Open in Who Shared Issue with article?

Now's the time to invest in biotech, according to VCs who've analyzed 1,227 early-stage biotech startups. Here's why they're so sure.

|
By Rodrigo Mallo Leiva, Eleonora Mantovani
| Business Insider Verified
"I invested in biotech once, and it only took me 12 years … to lose all my money." As venture capitalists investing in highly technical verticals, we've heard tech investors make this joke multiple times over the past few years. It's funny, but it might not be accurate anymore.
Open in Who Shared Issue with article?
See all 3 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified